Comparison of carbon-sulfur and carbon-amine bond in therapeutic drug: 4β-S-aromatic heterocyclic podophyllum derivatives display antitumor activity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Jian Long ^a   Zhao, Wei ^a   Zhou, Chen ^a   Zhang, Ya Xuan ^a   Li, Hong Mei ^a   Tang, Ya Ling ^b   Liang, Xin Hua ^b   Chen, Tao ^c   Tang, Ya Jie ^a  

^a HUBEI UNIVERSITY OF TECHNOLOGY   (China)

^b SICHUAN UNIVERSITY   (China)

^c TIANJIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4'-DEMETHYLEPIPODOPHYLLOTOXIN; AMINE; ANTINEOPLASTIC AGENT; CARBON; DNA TOPOISOMERASE (ATP HYDROLYSING); PLANT EXTRACT; PODOPHYLLOTOXIN; REACTIVE OXYGEN METABOLITE; SULFUR; TUBULIN;

AGONISTS; ANALOGS AND DERIVATIVES; APOPTOSIS; CELL CYCLE; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; HELA CELL LINE; HUMAN; LIVER CELL; METABOLISM; MICROTUBULE; MITOCHONDRION; PODOPHYLLUM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; ULTRASTRUCTURE;

AMINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL TRANSPORT; CARBON; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HEPATOCYTES; HUMANS; MICROTUBULES; MITOCHONDRIA; PLANT EXTRACTS; PODOPHYLLOTOXIN; PODOPHYLLUM; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REACTIVE OXYGEN SPECIES; SULFUR; TUBULIN;

EID: 84943272116     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14814     Document Type: Article

References (42)

1. Kamal, A., Ali Hussaini, S. M., Shaheer Malik, M. Recent Developments towards podophyllotoxin congeners as potential apoptosis inducers. Anticancer Agents Med Chem. 10, 565-574 (2014).
2. Gordaliza, M., Castro, M. A., Miguel del Corral, J. M., San Feliciano, A. Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Design. 6, 1811-1839 (2000).
3. Liu, Y. Q., Yang, L., Tian, X. Podophyllotoxin: Current Perspectives. Current Bioactive Compounds. 3, 37-66 (2007).
4. Bishop, J. F. et al. Etoposide in acute nonlymphocytic leukemia. Blood. 75, 27-32 (1990).
5. Bork, E. et al. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol. 4, 524-527 (1986).
6. Lima, L. M., Barreiro, E. J. Bioisosterism: A useful strategy for molecular modification and drug design. Curr Med Chem. 12, 23-49 (2005).
7. Patani, G. A., LaVoie, E. J. Bioisosterism: A rational approach in drug design. Chem Rev 96, 3147-3176 (1996).
8. Liu, J. M. et al. Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Can Chemother Pharmacol. 49, 425-428 (2002).
9. Bai, J. K., Zhao, W., Li, H. M., Tang, Y. J. Novel biotransformation process of podophyllotoxin to 4 ?-sulfur-substituted podophyllum derivatives with anti-tumor activity by Penicillium purpurogenum Y. J. Tang. Curr Med Chem. 19, 927-936 (2012).
10. Abad, et al. Synthesis, Antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins. J Med Chem. 55, 6724-6737 (2012).
11. Hili, R., Yudin, A. K. Making carbon-nitrogen bonds in biological and chemical synthesis. Nat Chem Bio. 2, 284-287 (2006).
12. Li, Y., Geng, J., Liu, Y., Yu, S., Zhao, G. Thiadiazole-a promising structure in medicinal chemistry. ChemMedChem. 8, 27-41 (2013).
13. Kharb, R., Sharma, P. C., Yar, M. S. Pharmacological significance of triazole scaffold. J Enzym Inhib Med Chem. 26, 1-21 (2011).
14. Ren, J. et al. Synthesis and biological evaluation of novel 4?-(1, 3, 4-oxadiazole-2-amino)-podophyllotoxin derivatives. Bioorg Med Chem Lett. 22, 4778-4782 (2012).
15. Reddy, M. D. et al. 4?-[(4-Alkyl)-1, 2, 3-triazol-1-yl] podophyllotoxins as anticancer compounds: Design, synthesis and biological evaluation. Eur J Med Chem. 46, 1983-1991 (2011).
16. Rabkin, M. T., Frederick, E. W., Lotz, M., Smith, L. H. Pyrimidine metabolism in man. v. the measurement in vivo of the biochemical effect of antineoplastic agents in animal and human subjects. J Clin Invest. 41, 871-883 (1962).
17. El Kouni, M. H. Potential chemotherapeutic targets in the purine metabolism of parasites. Pharmacol Ther. 99, 283-309 (2003).
18. Ravelli, R. B. et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 428, 198-202 (2004).
19. Massarotti, et al. The tubulin colchicine domain: a molecular modeling perspective. ChemMedChem. 7, 33-42 (2012).
20. Wu, C. C. et al. Structural basis of type II topoisomerase inhibition by the antitumor drug etoposide. Science. 333, 459-62 (2011).
21. Sackett, D. L. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol Ther. 59, 163-228 (1993).
22. Nitiss, J. L., Targeting, DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 9, 338-50 (2009).
23. Lee, K. H. et al. Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4?-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J Med Chem. 33, 1364-1368 (1990).
24. Shapiro, T. A., Englund, P. T. The structure and replication of kinetoplast DNA. Annu Rev Microbiol. 49, 117-43 (1995).
25. Shlomai, J. The structure and replication of kinetoplast DNA. Curr Mol Med 4, 623-47 (2004).
26. Surova, O., Zhivotovsky, B. Various modes of cell death induced by DNA damage. Oncogene. 32, 3789-97 (2013).
27. O'Connor, L. et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17, 384-395 (1998).
28. Mendez, G. et al. Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison Combretastatin-A4. Apoptosis. 16, 940-949 (2011).
29. Bratton, S. B. et al. Recruitment, activation and retention of caspases-9 and-3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J. 20, 998-1009 (2001).
30. Johnstone, R. W., Ruefli, A. A., Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108, 153-64 (2002).
31. Strasser, A., O'Connor, L., Dixit, V. M. Apoptosis signaling. Annu Rev Biochem 69, 217-45 (2000).
32. Hengartner, M. O. The biochemistry of apoptosis. Nature. 407, 770-6 (2000).
33. Helleday, T. et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 8, 193-204 (2008).
34. Ozben, T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 96, 2181-2196 (2007).
35. Gupta, S. C. et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16, 1295-1322 (2012).
36. Martindale, J. L., Holbrook, N. J. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 192, 1-15 (2002).
37. Moriwaki, Y., Yamamoto, T & Higashino, K. Enzymes involved in purine metabolism-A review of histochemical localization and functional implications. Histology and Histopathology 14, 1321-1340 (1999).
38. Jager, L. P., van der Schaar, M. W. G. Actions of purine compounds on the cell membrane of porcine colonic circular smooth muscle. Eur J Pharmacol. 183, 1204 (1990).
39. Müller, M. M., Kraupp, M., Chiba, P. Helmut Rumpold. Regulation of purine uptake in normal and neoplastic cells. Adv Enyzyme Regul. 21, 239-256 (1983).
40. Wang, L. et al. Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. J Med Chem. 55, 1758-1770 (2012).
41. Diaz, J. F., Andreu, J. M. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 32, 2747-2755 (1993).
42. Andreu, J. M., Gorbunoff, M. J., Lee, J. C., Timasheff, S. N. Interaction of tubulin with bifunctional colchicine analogues: an equilibrium study. Biochemistry. 23, 1742-1752 (1984).